Princewill Kum Unji, Alex Mambap Tatang, Samuel Angwafor, Loveline Lum Niba, Adji Minette Jaqueline Porro, Denis Nsame Nforniwe, Andreas Chiabi
{"title":"The effectiveness of COVID-19 Heterologous Vaccination: the experience from a Regional Hospital in Cameroon.","authors":"Princewill Kum Unji, Alex Mambap Tatang, Samuel Angwafor, Loveline Lum Niba, Adji Minette Jaqueline Porro, Denis Nsame Nforniwe, Andreas Chiabi","doi":"10.4314/ahs.v24i4.11","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>With most COVID-19 vaccines requiring at least 2 doses, heterologous vaccination will facilitate vaccination programs where vaccine supplies fluctuate. However, with insufficient data on effects of heterologous vaccination in our setting, people remain reluctant to mix.</p><p><strong>Objectives: </strong>We seek to assess the effects of heterologous vaccination on morbidity and mortality.</p><p><strong>Methods: </strong>This was a 7 months retrospective study for COVID-19 patients managed by the Bamenda Regional Hospital, Cameroon, running from the 18th August 2021 to 28<sup>th</sup> February 2022. Logistic regression used to asses relationship between predictors and outcome.</p><p><strong>Results: </strong>Our 1254 participants had a mean age of 50.1(±19.6) years, we had 24 (1.9%) being fully vaccinated, where 7 (29.2%) took heterologous vaccines. Also, 721 (57.5%) had the moderate/severe form of the disease. Those fully vaccinated had lower odds of having severe disease (p=0.037). However, heterologous vaccination compared to homologous vaccination had no significant difference on morbidity (p=0.729). Among patients who died, none was fully vaccinated.</p><p><strong>Conclusion: </strong>The protective effect of vaccination on morbidity was similar in those with heterologous vaccination as well as those who took.</p>","PeriodicalId":94295,"journal":{"name":"African health sciences","volume":"24 4","pages":"85-90"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970136/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"African health sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4314/ahs.v24i4.11","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: With most COVID-19 vaccines requiring at least 2 doses, heterologous vaccination will facilitate vaccination programs where vaccine supplies fluctuate. However, with insufficient data on effects of heterologous vaccination in our setting, people remain reluctant to mix.
Objectives: We seek to assess the effects of heterologous vaccination on morbidity and mortality.
Methods: This was a 7 months retrospective study for COVID-19 patients managed by the Bamenda Regional Hospital, Cameroon, running from the 18th August 2021 to 28th February 2022. Logistic regression used to asses relationship between predictors and outcome.
Results: Our 1254 participants had a mean age of 50.1(±19.6) years, we had 24 (1.9%) being fully vaccinated, where 7 (29.2%) took heterologous vaccines. Also, 721 (57.5%) had the moderate/severe form of the disease. Those fully vaccinated had lower odds of having severe disease (p=0.037). However, heterologous vaccination compared to homologous vaccination had no significant difference on morbidity (p=0.729). Among patients who died, none was fully vaccinated.
Conclusion: The protective effect of vaccination on morbidity was similar in those with heterologous vaccination as well as those who took.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
